---
title: "Viridian Therapeutics Secures $889 Million Financing and Submits BLA for Veligrotug"
description: "Viridian Therapeutics Inc. has secured up to $889 million in financing through various arrangements and amended its credit facility with Hercules Capital for an additional $300 million. The company su"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264427228.md"
published_at: "2025-11-05T12:10:10.000Z"
---

# Viridian Therapeutics Secures $889 Million Financing and Submits BLA for Veligrotug

> Viridian Therapeutics Inc. has secured up to $889 million in financing through various arrangements and amended its credit facility with Hercules Capital for an additional $300 million. The company submitted a Biologics License Application for veligrotug for thyroid eye disease, aiming for a U.S. launch in mid-2026. Upcoming data readouts for VRDN-003 are expected in early 2026. Viridian anticipates that its current cash and expected revenues will support its business plans until profitability.

Viridian Therapeutics Inc. reported its third quarter 2025 financial results and recent business progress. The company completed a set of financing transactions in October 2025, securing access to up to $889 million in potential capital through equity, royalty, and credit arrangements. Viridian also amended its credit facility with Hercules Capital, providing up to $300 million in available capital and extending the interest-only payment period. The company announced the successful submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for veligrotug in thyroid eye disease (TED), with preparations underway for a potential U.S. commercial launch in mid-2026, pending approval under a Priority Review timeline. Topline data readouts for subcutaneous VRDN-003 were accelerated, with REVEAL-1 data expected in Q1 2026 and REVEAL-2 in Q2 2026, after both studies exceeded enrollment targets. Viridian stated that its current cash, anticipated near-term royalty milestones, and expected commercial revenues from veligrotug and VRDN-003, if approved, are projected to fund its business plans through profitability. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-265711), on November 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HTGC.US - Hercules Capital](https://longbridge.com/en/quote/HTGC.US.md)
- [VRDN.US - Viridian Therapeutics](https://longbridge.com/en/quote/VRDN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FDA Accepts Viridian Therapeutics' Veligrotug BLA for Priority Review | Viridian Therapeutics Inc. announced that the FDA has accepted its Biologics License Application for veligrotug under Pr | [Link](https://longbridge.com/en/news/271647218.md) |
| FDA Accepts Viridian's Veligrotug BLA For Priority Review In Thyroid Eye Disease | Viridian Therapeutics Inc. announced that the FDA has accepted its Biologics License Application for Veligrotug, a treat | [Link](https://longbridge.com/en/news/270580152.md) |
| Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit | Savara (NASDAQ:SVRA) executives provided an update on the regulatory timeline and preparations for MOLBREEVI, aimed at t | [Link](https://longbridge.com/en/news/276009532.md) |
| Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit | Zenas BioPharma's CEO Lonnie Moulder discussed the company's progress and future plans for obexelimab during the Guggenh | [Link](https://longbridge.com/en/news/276045637.md) |
| FDA Grants Priority Review to Viridian Therapeutics' Veligrotug for Thyroid Eye Disease | Viridian Therapeutics announced that the FDA has accepted the Biologics License Application for veligrotug, a treatment  | [Link](https://longbridge.com/en/news/270488222.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.